Panacea Biotec Share Price

Indias leading researchbased health management company with established research, manufacturing and marketing capabilities are collectively known as Panacea Biotec Limited (PBL), which was incorporated on February 2, 1984 under the name of Panacea Drug (P) Ltd. A second largest vaccine producer in India has the product portfolio of highly innovative prescription products in important therapeutic areas such as pain management, diabetes management, renaldisease management, antiosteoporosis, antitubercular, gastrointestinal care products and vaccines. The Company has collaborations and tieups with leading national and international research organizations and corporations. PBL has ultra modern, stateofart production facilities at Himachal Pradesh, Punjab Delhi for manufacturing vaccines and pharmaceutical formulations comply with the USFDA, UKMHRA, SAMCC and WHOcGMP standards and it has four research and development centers. The plant for vaccines production (Radicura Pharma) and pharmaceutical formulations plant (Panacea Drug P Ltd) at New Delhi were established during the year 1988 and 1989 respectively. In 1993, merger of Panacea Drugs (P) Ltd and Radicura Pharma gave the name Panacea Biotec Ltd. The Company made its Initial Public Offering (IPO) in the year of 1995 and also in the same year, PBL had formed state of the art Drug Delivery RD centre at Lalru. In the year 1997, the company obtained its first product patent in several countries. PBLs Research Development made a tie up with European MNC in the year 2001 and in 2002, an inlicensing agreement was made with Biotechnology Consortium of India for development commercialization of Anthrax Vaccine. Also in the identical year of 2002, the company had commissioned Recombinant Vaccine production plant. During the year 2004, PBL made an inlicensing agreement with National Institute of Immunology, New Delhi, for Japanese Encephalitis Candidate Vaccine, marketing joint venture with Chiron (now Novartis) Vaccines, UK and also made collaboration with Cambridge Biostability, UK, for Thermo Stable Vaccines. After a year in 2005, an inlicensing agreement was prepared with National Institute of Health, USA for Hair Growth Hormone. During the year 2006, ultra modern Pharmaceuticals formulation facility at Baddi, Himachal Pradesh was goes live, which has WHO cGMP complaint. Landmark collaborations were made with The Netherlands Vaccine Institute (The Nederlands Vaccin Institute (NVI)) for manufacture marketing of finished Inactivated Polio Vaccine (IPV) and a number of IPV based combination vaccines in India and across the globe. Collaboration was happened with PT.Bio Farma to manufacture market Measles Vaccine. Also in the same year of 2006, the company had inaugurated its Biopharmaceutical RD Centre at New Delhi and made collaboration with National Research Development Corporation (NRDC) for technology transfer of Foot and Mouth Vaccine. Vaccine Formulation Plant of the company was established at Baddi in the year 2007 and the research agreement was made with Punjab University to develop New Chemical Entities for Psychiatric Disorders. PBL forayed into Healthcare Delivery in the year 2008, made a collaboration to setup 220 bed multi superspecialty hospital in NCR and also the company obtained a patent (Patent No. 7,371,412 B2) from US Patent Trademark Office for the product Thank GodTM (Euphorbia Prostrata) for effective management of hemorrhoids piles in the identical year of 2008.During year 200809, Companys Joint Venture Company, Chiron Panacea Vaccines Pvt. Ltd. (CPV), setup for marketing of innovativecombination and other vaccines in India has launched Hepatitis A vaccine HAVpur, in collaboration with Berna Biotech Ltd., Switzerland and the Companys Injectable Polio Vaccine PolProtecand monohib Vaccine (novoHib) in the Indian market.During the year 200809, the Companys associate firm, viz. M/s Lakshmi The Manager, in which the Company had invested Rs.40 million (40% share), was taken over by a newly formed company, Lakshmi Manager Holdings Limited. As a result of takeover ofthe said firm, the Company has been allotted Equity Shares for an amount of Rs.41 .3 million in the said company.The Company had launched generic product Tacrolimus in Germany in 2011 under the brand Tacpan through Companys indirect wholly owned subsidiary company Panacea Biotec Germany GmbH (PBGG).In 2013, Companys 50:50 joint venture Adveta Power Pvt. Ltd with its associate PanEra Biotec Pvt. Ltd, incorporated to generate and distribute power or any other energy from conventional / nonconventional energy sources on a commercial basis. During the year 201314, the Company disposed of entire shareholding in its erstwhile WOS, Lakshmi Manager Holdings Ltd. (LMH). Post such disposal, LMH and its WOS Trinidhi Finance Pvt. Ltd. and subsidiary Best General Insurance Company Ltd. ceased to be the subsidiaries of the Company w.e.f. 25 January, 2014. During the year 2015, the Company launched new products in various therapeutic categories including: Glizid M V ( Voglibose, Gliclaz ide Metformin Hydrochloride) Antidiabetic Calcom Plus (Coral Calcium, Vitamin D3 Vitamin K27) Orthopedic segment and RF Willgo (Paracetamol and Aceclofenac) Pain management and To Plus (Paracetamol etc.) Anticold. During 2016, Company introduced Indias first indigenously developed high quality Oncology product, CABAPAN (Cabazitaxel) Injection, for treatment of metastatic Castration Resistant Prostrate Cancer (mCRPC). Further, it introduced indigenously antidiabetic drug, TENEPAN (Teneligliptin), for treatment of Type 2 Diabetes Mellitus (T2DM). In December 2016, it launched worlds first fully liquid tetravalent vaccine, EasyfourTT for active primary immunization and booster dose against Diphtheria, Tetanus, Pertussis (DTwP) and Haemophilus Influenza Type B (Hib).In March, 2017, it launched first liquid whole cell pertussis (wP) based Hexavalent Combination vaccine, EasySixTM. The Company had one subsidiary, viz. NewRise Healthcare Private Limited, which consequently ceased to be subsidiary of the Company effective from April 21, 2017.The Board of Directors of the Company had, at its meeting held on May 30, 2019 approved the Scheme of Arrangement between the Company and Ravinder Heights Limited (RVHL) and their respective shareholders and creditors for demerger of real estate business of the Company comprising of Radhika Heights Limited along with its step down subsidiaries and two real estate properties, into RVHL, which was approved from April 01, 2019 and the Scheme became effective from September 10, 2020.During the current year 2020, Radhika Heights Limited (RHL) along with its step down subsidiaries and two real estate properties, were demerged into RVHL and RHL and its subsidiaries have ceased to be the subsidiary of the Company w.e.f. September 10, 2020.During the FY 201920, the Company transferred its pharmaceutical formulations business including pharmaceutical formulations facility at Baddi and related research development and natural products extraction activities at Lalru, to its wholly owned subsidiaryviz. Panacea Biotec Pharma Limited (PBPL) by way of slump sale on going concern basis, which completed with effect from February 1, 2020. As on March 31, 2021, Panacea Biotec Pharma Limited (PBPL ) became a material subsidiary of Company. The Company and PBPL entered into definitive agreements on February 28, 2022 for sale of Pharmaceutical Formulations Brandsof PBPL in India and Nepal to Mankind Pharma Limited at an aggregate consideration of Rs.18,720 million. As part of this arrangement, Mankind retained PBPLs welltrained sales and marketing team engaged in the pharmaceutical formulations business and saidtransaction was completed on March 3, 2022.During the year 2024, Company has launched worlds first fully liquid wPIPV based pentavalent vaccine, EasyFourPol (DTwPHibIPV) in India. Companys vaccine manufacturing facilities were inspected by WHO for the pentavalent vaccine EasyveTT and BiOPV. The said inspection was completed without any critical observation. Companys wholly owned subsidiary, Panacea Biotec Pharma Limited (PBPL) has launched the nanotechnologybased generic product, Paclitaxel protein bound in human albumin particles.

Panacea Biotec reported a Q1 FY 2025-26 revenue of ₹166.7 crore, down -0.9% YoY, with net profit increased 481.3% to ₹3.96 crore. For the full year FY2025–2026, revenue reached ₹579.75 crore and profit touched at ₹-8.72 crore. As of Jun '25, Panacea Biotec’s market capitalisation stood at ₹2,511.89 crores. Shareholding as of Jun '25 shows promoters holding 72.5%, with FIIs at 0.8%, DIIs at 25.2%, and public at %.

As of 19 Aug, 2025, Panacea Biotec share price is ₹410.1. The stock opened at ₹409.8 and had closed at ₹408.3 the previous day. During today’s trading session, Panacea Biotec share price moved between ₹406.00 and ₹414.80, with an average price for the day of ₹410.40. Over the last 52 weeks, the stock has recorded a low of ₹161.42 and a high of ₹581.90. In terms of performance, Panacea Biotec share price has increased by 27.2% over the past six months and has increased by 110.86% over the last year.